SEC Form 4
Vivos Therapeutics, Inc. (VVOS) insider trading
In the 12 months to Oct 26, 2026, one VVOS insider reported open-market purchases of $1.8M across 1 filing; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $1.8M
- 1 filing · Michael C. Skaff, 10% owner
Who traded VVOS, and when
- Purchase
VVOS daily close from Oct 27, 2025 to Oct 26, 2026, between $0.13 and $2.72, last $0.13. 0 sale and 1 purchase filings by 1 insider, marked at their filing dates. Michael C. Skaff, 10% owner: bought $1.8M across 1 filing, first filed Apr 2, 2026, last Apr 2, 2026.
Largest mark · tap a row for others
Michael C. Skaff · 10% owner
Purchase $1,813,858
1,353,625 shares at $1.34 avg
Filed Apr 2, 2026 · traded Mar 31
Close on filing date $1.32
Michael C. Skaff · 10% owner
10% owner
$1.8M boughtOpen-market trades
1 filing in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Michael C. Skaff | 10% owner | — | $1.8M | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Michael C. Skaff 10% owner | Purchase | 1,353,625 | $1.34 | $1.8M | 1,044,777 |
GET /stocks/filings/vX/form-4?tickers=VVOS&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"VVOS"
],
"issuer_cik": "0001716166",
"owner_cik": "0002114460",
"accession_number": "0002074003-26-000008",
"form_type": "4",
"filing_date": "2026-04-02",
"period_of_report": "2026-03-31",
"issuer_name": "Vivos Therapeutics, Inc.",
"issuer_trading_symbol": "VVOS",
"owner_name": "V-Co Investors 3 LLC",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-03-31",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 308848,
"transaction_price_per_share": 1.34,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 1353625,
"transaction_value": 413856.32,
"direct_or_indirect": "I",
"nature_of_ownership": "By V-CO Investors 3 LLC",
"footnotes": [
{
"id": "F2",
"description": "Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."
}
]
},
{
"tickers": [
"VVOS"
],
"issuer_cik": "0001716166",
"owner_cik": "0002074003",
"accession_number": "0002074003-26-000008",
"form_type": "4",
"filing_date": "2026-04-02",
"period_of_report": "2026-03-31",
"issuer_name": "Vivos Therapeutics, Inc.",
"issuer_trading_symbol": "VVOS",
"owner_name": "Skaff Michael C",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-03-31",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 308848,
"transaction_price_per_share": 1.34,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 1353625,
"transaction_value": 413856.32,
"direct_or_indirect": "I",
"nature_of_ownership": "By V-CO Investors 3 LLC",
"footnotes": [
{
"id": "F2",
"description": "Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 2 records
- Grants and awards1 record
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Vivos Therapeutics, Inc.'s CEO sold stock?
No. Ronald Kirk Huntsman (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is VVOS’s insider data?
These are VVOS Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track VVOS insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for VVOS every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.